Oncolytics Biotech (ONC) Stock Price, News & Analysis

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Key Stats

• Today's Range: C$1.15 to C$1.29
• 50-Day Range: C$1.10 to C$1.85
• 52-Week Range: C$1.02 to C$2.08
• Volume: 242,165 shs
• Average Volume: 77,645 shs
• Market Capitalization: C$91.46 million
• P/E Ratio: N/A
• Dividend Yield: 0.31%
• Price Target: C$3.50
• Consensus Rating: Buy

Oncolytics Biotech Stock Analysis - MarketRank™

Oncolytics Biotech scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oncolytics Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncolytics Biotech is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncolytics Biotech is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oncolytics Biotech has a P/B Ratio of 4.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ONC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Oncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Oncolytics Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ONC.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.48

News Sentiment

Oncolytics Biotech has a news sentiment score of -0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.

MarketBeat Follows

4 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.82% of the stock of Oncolytics Biotech is held by insiders.

Percentage Held by Institutions

Only 1.75% of the stock of Oncolytics Biotech is held by institutions.

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed this year?

Oncolytics Biotech's stock was trading at C$1.79 at the start of the year. Since then, ONC shares have decreased by 33.5% and is now trading at C$1.19.
View the best growth stocks for 2024 here.

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and Barrick Gold (GOLD).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:ONC
• CUSIP: N/A
• CIK: N/A
• Web: www.oncolyticsbiotech.com
• Phone: +1-403-6707380
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$3.50
• High Stock Price Target: C$3.50
• Low Stock Price Target: C$3.50
• Potential Upside/Downside: +194.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-28,020,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -138.22%
• Return on Assets: -71.33%

Debt

• Debt-to-Equity Ratio: 6.09
• Current Ratio: 4.99
• Quick Ratio: 8.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.28 per share
• Price / Cash Flow: 4.22
• Book Value: C$0.24 per share
• Price / Book: 4.96

Miscellaneous

• Outstanding Shares: 76,860,000
• Free Float: N/A
• Market Cap: C$91.46 million
• Optionable: Not Optionable
• Beta: 1.35